Credit: Jo Panuwat D/Shutterstock. On November 18, at the American Heart Association (AHA) 100th Annual Meeting 2024, the ...

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...

Long-acting (LA) glucagon-like peptide-1 (GLP-1) receptor agonists (RAs ... Development of antidrug antibodies are common with the LA GLP1-RAs (except for dulaglutide), but there is little ...

[11] The absence of severe hypoglycemia is consistent with the glucose-dependent insulinotropic mechanism of GLP-1 receptor agonists. The rates of confirmed hypoglycemia were similar between the ...

Structure Therapeutics Inc. (NASDAQ:GPCR) was able to report positive results from its phase 2a study using its GLP-1R agonist GSBR-1290 for the treatment of patients with obesity in June 2024.

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

And we had tried small molecules [GLP-1 receptor agonists] too ... because I was very focused on avoiding an antibody response. [Liraglutide has 97% homology with native GLP-1, with just one ...

Lexaria Bioscience (LEXX) has engaged a contract research organization to perform the world’s first-ever fluorescently tagged ...

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 receptor (GLP-1R) agonist, Rybelsus, which is currently approved for type 2 ...

A mid-stage trial designed to evaluate the antibody therapy in combination ... data in increasing lean muscle when used with ...

Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also ...